Volume 85 Issue 35 | p. 23 | Concentrates
Issue Date: August 27, 2007

Abraxis Acquires Drug From Scripps

Department: Business | Collection: Green Chemistry, Economy

Abraxis BioScience has licensed a potential cancer drug from Scripps Research Institute for an undisclosed sum. Abraxis will evaluate the therapeutic potential of the epothilone agent in combination with its "nab" technology, which uses human protein albumin to carry an anticancer drug to its target. The company claims the delivery method allows high concentrations of the drug to reach tumors while reducing side effects associated with solvent-based delivery systems. Abraxis also gains the rights to 11 other potential drug candidates, one of which could be chosen for clinical development.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment